SAN DIEGO, Oct. 25, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, disclosed today that U.S. Patent number 8,288,172 was issued to the Company by the U.S. Patent and Trademark Office (USPTO) on October 16 th, 2012. The patent entitled "Extracorporeal Removal of Microvesicular Particles," provides Aethlon Medical the exclusive right to remove immune suppressive microvesicular particles, which include but are not limited to exosomes from the circulation of treated patients. A therapy able to inhibit or reduce the presence of cancer-secreted exosomes would address a significant unmet medical need in the effort to combat cancer.
The Aethlon Hemopurifier®, which is a first-in-class medical device to treat Hepatitis C virus (HCV), has also been validated to capture exosomes underlying breast cancer, ovarian cancer, metastatic melanoma, colorectal cancer, and lymphoma during preclinical in vitro studies.
Cancer-secreted exosomes promote tumor progression by inducing apoptosis or programmed cell death of anti-cancer immune cells. As a result of inhibiting the immune response, exosomes increase the proliferation and spread of many forms of cancer. The particles also promote angiogenesis (essential for tumor survival and growth), increase tumor aggressiveness, and contribute to anti-cancer drug resistance. Researchers have recently discovered that cancer-secreted exosomes also seed the formation and spread of tumor metastasis."The issuance of this patent sets the stage for advancing our Hemopurifier® as an adjunct cancer therapy, and at the same time restricts the market emergence of other extracorporeal strategies to address this vital therapeutic target," stated Jim Joyce, Chairman and CEO at Aethlon Medical. In addition to granting Aethlon the exclusive right to remove microvesicular particles (including exosomes), the patent describes a method to bind and capture immune suppressive microvesicular particles from blood with a medical filtration device containing single or multiple affinity agents, which can include antibodies, aptamers, beads, lectins, proteins, or other compounds that adhere to microvesicles or exosomes, which are also referred to as epididimosomes, argosomes, exosome-like vesicles, microparticles, promininosomes, prostasomes, dexosomes, texosomes, dex, tex, archeosomes and oncosomes.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV